Raymond Schinazi Joins Precision BioSciences Board of Directors

Globally recognized leader in antiviral drug discovery and development

DURHAM, N.C.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/celltherapy?src=hash" target="_blank"gt;#celltherapylt;/agt;–Precision BioSciences (“Precision”), a genome editing company dedicated
to improving life (DTIL) through its proprietary ARCUS genome editing
platform, has appointed Raymond Schinazi, PhD, Hon DSc to its board of
directors. Dr. Schinazi is the Frances Winship Walters Professor of
Pediatrics and director of the Laboratory of Biochemical Pharmacology at
Emory University.

“The cutting-edge technology developed by the Precision BioSciences team
provides new opportunities to combat viral diseases like hepatitis B
virus (HBV),” said Dr. Schinazi. “Their proprietary genome editing
platform, ‘ARCUS,’ has the potential to enable alternative innovative
therapies to safely and efficiently silence genes essential for viruses
that cause significant human morbidity and mortality.”

“Dr. Schinazi’s expertise in virology and preclinical and clinical drug
development will be invaluable as our company continues the development
of our platform to tackle the problem of HBV and other viruses,” said
Precision CEO Matt Kane. “His dedication to addressing unmet need in
viral disease and his understanding of ARCUS at the mechanistic level
make him an ideal board member as we work to build an innovative
antiviral genome editing program.”

Dr. Schinazi’s distinguished
career in drug discovery includes co-founding several biotechnology
companies, including Triangle Pharmaceuticals and Pharmasset, Inc. He is
also a Charter Fellow of the National Academy of Inventors and a Fellow
of the American Society of Microbiology. He received a BSc and PhD in
chemistry and DSc in biotechnology from the University of Bath. Dr.
Schinazi also serves on the board of directors of Brace Pharma Capital
and the board of trustees of amfAR.

About Precision BioSciences

Precision BioSciences is dedicated to improving life (DTIL) through its
proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS
in the development of its product candidates, which are designed to
treat human diseases and create healthy and sustainable food and
agriculture solutions. Precision is actively developing product
candidates in three innovative areas: allogeneic CAR T immunotherapy, in
vivo gene correction, and food. For additional information, please
visit www.precisionbiosciences.com

Contacts

Precision BioSciences:
Heather King
+1 919-314-5512
[email protected]